Cite
A phase II study with low dose decitabine, a DNA hypomethylating pyrimidine analogue, in high risk MDS patients.
MLA
UCL - Cliniques universitaires Saint-Luc, et al. “A Phase II Study with Low Dose Decitabine, a DNA Hypomethylating Pyrimidine Analogue, in High Risk MDS Patients.” Blood, Vol. 92, No. 10, p. 632A-632A (1998), 1998. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1130548492&authtype=sso&custid=ns315887.
APA
UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, Wijermans, P., Ferrant, A., Lubbert, M., Verhoef, G., Bosly, A., Ravoet, C., & André, M. (1998). A phase II study with low dose decitabine, a DNA hypomethylating pyrimidine analogue, in high risk MDS patients. Blood, Vol. 92, No. 10, p. 632A-632A (1998).
Chicago
UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, P Wijermans, Augustin Ferrant, M Lubbert, G. Verhoef, André Bosly, C Ravoet, and Marc André. 1998. “A Phase II Study with Low Dose Decitabine, a DNA Hypomethylating Pyrimidine Analogue, in High Risk MDS Patients.” Blood, Vol. 92, No. 10, p. 632A-632A (1998). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1130548492&authtype=sso&custid=ns315887.